Related Experiment Video
Updated: May 12, 2026
06:11
Monitoring Blood Glucose in Mouse Offspring After Intracytoplasmic Sperm Injection
Published on: May 17, 2024
Glycemic control and fetal abdominal circumference.
S Gopinath1, G Varalakshmi, K Manoj
1Pondicherry Speciality Centre, Pondicherry, India.
Indian Journal of Endocrinology and Metabolism
|April 9, 2013
Summary
Gestational diabetes (GDM) impacts fetal growth. Poor glycemic control in GDM correlates with increased fetal abdominal circumference and higher birth weight, highlighting risks for newborns.
Area of Science:
- Obstetrics and Gynecology
- Endocrinology
- Perinatology
Background:
- Gestational diabetes mellitus (GDM) affects maternal and fetal health.
- Monitoring fetal growth is crucial in GDM pregnancies.
- Glycemic control is a key factor in managing GDM.
Purpose of the Study:
- To investigate the correlation between glycemic status and fetal abdominal circumference in GDM patients.
- To examine the relationship between fetal abdominal circumference and birth weight in GDM.
- To understand the impact of glycemic control on fetal development in GDM.
Main Methods:
- Study included 75 women with gestational diabetes mellitus (GDM).
- Assessed anthropometry and glycemic profiles (HbA1C).
- Measured fetal abdominal circumference via ultrasound and recorded birth weight post-delivery.
Main Results:
- Fetal abdominal circumference showed a significant correlation with glycemic control.
- Increased fetal abdominal circumference was associated with higher fetal birth weight.
- Fluctuating glycemic levels in GDM patients were linked to these findings.
Conclusions:
- Glycemic status is closely linked to fetal abdominal circumference and birth weight in GDM.
- Monitoring fetal abdominal circumference can aid in assessing risks associated with GDM.
- Effective glycemic management is essential to mitigate adverse fetal outcomes in GDM.
Related Concept Videos
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
01:20Pathophysiology of Diabetes
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
01:29Hyperglycemia
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...